

New Results Uphold High-Dose Statin for CHD

BY MITCHEL L. ZOLER
Philadelphia Bureau

DALLAS — Aggressive statin therapy is now the standard of care for patients with established coronary heart disease, even though the results from the most recent major test of a high-dose statin regimen failed to show a statistically significant benefit, compared with a lower-dose statin regimen, in almost 9,000 patients.

The 11% relative reduction in major coronary events (death, myocardial infarction, or cardiac arrest and resuscitation) seen in the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) study, which compared an 80-mg/day regimen of atorvastatin against a 20-mg or 40-mg/day regimen of simvastatin, was “consistent with the results of other statin trials, such as PROVE-IT and TNT,” Dr. Terje R. Pedersen said at the annual scientific sessions of the American Heart Association.

“There is no doubt that lower levels of low-density lipoprotein cholesterol are better,” said Dr. Pedersen, a professor of medicine and director of the Center for Preventive Medicine at Ullevål University Hospital, Oslo. He was the lead investigator for the IDEAL study, which was published concurrently with his report at the meeting (JAMA 2005;294:2437-45).

The results of both IDEAL and TNT (Treating to New Targets) “strengthened the case for incremental benefits from lowering LDL cholesterol well below 100 mg/dL,” commented Dr. Scott Grundy, director of the Center for Human Nutrition at the University of Texas Southwestern Medical Center in Dallas. Regimens that produce very low levels of LDL cholesterol “will be increasingly accepted as the standard treatment for secondary prevention.”

“Results from a single trial are sometimes hard to interpret. The results from IDEAL, TNT, PROVE-IT [Pravastatin or Atorvastatin Evaluation and Infection Therapy], REVERSAL [Reversal of Atherosclerosis With Aggressive Lipid Lowering], and other trials may not always reach statistical significance, but if you put them all together, people are moving toward more intensive statin treatment,” commented Dr. Steven E. Nissen, medical director of the Cardiovascular Coordinating Center at the Cleveland Clinic. “You should try to get the LDL cholesterol as low as you can, safely. In both IDEAL and TNT, most patients did not get to 70 mg/dL or less, but even if only 25%-35% of patients get there, that’s good.”

IDEAL enrolled 8,888 patients aged 80 or younger who had a history of a definite myocardial infarction and who qualified for statin therapy based on national treatment guidelines at the time of enrollment. Patients were entered at 190 ambulatory cardiology and private specialist centers in Denmark, Finland, Iceland, the Netherlands, Norway, and Sweden from March 1999 to March 2001. Patients were randomized to treatment with either 20 mg/day simvastatin or 80 mg/day atorvastatin and followed for an average of 4.8 years.

After the first 24 weeks of treatment,

21% of patients in the simvastatin group had their dosage raised to 40 mg/day; by the end of the study, 23% of patients in the simvastatin group were receiving 40 mg/day, with the rest on 20 mg/day. By the end of the study, 13% of patients in the atorvastatin group had their dosage reduced to 40 mg/day.

The incidence of major coronary events was 10.4% in the simvastatin group and 9.3% in the atorvastatin group, an 11% relative risk reduction that fell slightly short

of statistical significance. But Dr. Pedersen said that other secondary end points showed statistically significant differences in favor of the high-dose group, including a 13% relative reduction in major cardiovascular disease events and a 16% cut in any coronary heart disease event.


With safety data from almost 4,000 patients treated with 80 mg/day of atorvastatin for almost 5 years, the results also bolstered the apparent safety of aggressive lipid lowering. The results showed no dif-

ference between the two groups in all-cause mortality, and no difference between the two study groups in the incidence of serious adverse events. A small proportion of patients, less than 1.5%, had major liver enzyme elevations on the 80 mg/day regimen. Myopathy was diagnosed in 0.14% of patients on this regimen, and 0.05% had rhabdomyolysis.

The IDEAL study was sponsored by Pfizer Inc. Dr. Pedersen has been a consultant to and a speaker for Pfizer. ■

For your patients with type 2 diabetes, start with simple QD dosing¹

Once-a-day dosing gets 41% of patients to ADA goal (<7% A1C)¹




*Patients achieving AACE-recommended A1C goal $\leq 6.5\%$ on average experienced a 2.4% reduction from baseline. Multicenter, observational, treat-to-target 48-week trial in 100 patients with type 2 diabetes taking 12 U NovoLog Mix 70/30 once daily before supper plus oral therapy initiated before trial start. In some patients, PM secretagogues were discontinued or reduced during trial. Three-month run-in period included continuation of oral therapy or basal insulin. Results include phase 1 (16 weeks). Patients not achieving AACE-recommended A1C goal $\leq 6.5\%$ continued to phase 2.

Start QD
Assess control over time
Intensify with BID

Intensify with BID dosing^{1,2}

Once- and twice-a-day dosing gets 70% of patients to ADA goal (<7% A1C)^{1,2†}



†Results from phases 1 and 2. Patients not achieving A1C goal $\leq 6.5\%$ were transitioned to BID dosing in phase 2. Patients not achieving A1C goal $\leq 6.5\%$ continued to phase 3.

No increase in incidence of major hypoglycemia from QD to BID dosing^{1,2}

NovoLog Mix 70/30 provides simple All-in-1 Coverage for patients with type 2 diabetes

- Effective A1C control, with both PPG and FPG coverage³
- Once-a-day dosing with the option to intensify^{1,2}
- Low rate of hypoglycemia^{4,5}; no NPH
- Preferred insulin delivery device⁶
- Covered under most managed care formularies



Now offering Satisfaction Guarantee[†] to help patients progress toward glycemic goals.

[†]Subject to program details included in Satisfaction Guarantee Patient Folio.

NovoLog Mix 70/30
70% insulin aspart protamine suspension and 30% insulin aspart injection, (rDNA origin)

Indications and Usage

- NovoLog Mix 70/30 is indicated for the treatment of patients with diabetes mellitus for the control of hyperglycemia

Important Safety Information

- Because NovoLog Mix 70/30 has peak pharmacodynamic activity 1 hour after injection, it should be administered with meals. Hypoglycemia is the most common adverse effect of insulin therapy, including NovoLog Mix 70/30. NovoLog Mix 70/30 is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog Mix 70/30 or one of its excipients. Potential side effects associated with the use of all insulins include hypoglycemia, hypokalemia, lipodystrophy, and allergic reactions. Because of differences in the action of NovoLog Mix 70/30 and other insulins, care should be taken in patients in whom these conditions may be clinically relevant (eg, patients who are fasting, have autonomic neuropathy, are using potassium-lowering drugs, or are taking drugs sensitive to serum potassium level). Do not mix NovoLog Mix 70/30 with any other insulin product
- Because there is diurnal variation in insulin resistance and endogenous insulin secretion, variability in the time and content of meals, and variability in the time and extent of exercise, fixed-ratio insulin mixtures may not provide optimal glycemic control for all patients

Please see brief summary of full Prescribing Information next page.

References: 1. Jain R, Wahl T, Wahlen J, Bressler P, Hu P, Allen E. Patients with type 2 diabetes can achieve A1C targets with once-daily biphasic insulin aspart 70/30 before supper [abstract 547-P]. *Diabetes*. 2004;53(suppl 2):A130. 2. Data on file. Novo Nordisk Inc. 3. Raskin P, Allen E, Hollander P, et al, for the INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. *Diabetes Care*. 2005;28:260-265. 4. Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. *Diabet Med*. 2002;19:393-399. 5. Boehm BO, Vaz JA, Brøndsted L, Home PD. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. *Eur J Intern Med*. 2004;15:496-502. 6. Niskanen L, Jensen LE, Råstam J, Nygaard-Pedersen L, Erichsen K, Vora JP. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin Ispro 25 and pen devices in adult patients with type 2 diabetes mellitus. *Clin Ther*. 2004;26:531-540.

© 2005 Novo Nordisk Inc. October 2005 128916